CHU PHARMA exhibited at both CPHI Shanghai in the first half of the year and API China in the autumn, showcasing its three major business segments: generic drug APIs, innovative GLP-1 APIs, and customized injection manufacturing. The company focused on connecting with emerging pharmaceutical markets in Uzbekistan, Azerbaijan, and Turkmenistan in Central Asia, adding 8 new long-term distributors and further improving its channel network in countries along the Belt and Road Initiative.